EFB announces clinical results for Cerebraca® Wafer at ASCO 2026
The wafer showed potential to reverse chemoresistance and a Phase IIb/III trial has started.
Latest Everfront Biotech News & Updates
See the latest news and media coverage for EFB. We track all announcements, press releases, and industry mentions in real time, all in one place.
Last updated
Latest news about Everfront Biotech (EFB)
In short: EFB advanced its Cerebraca Wafer for glioblastoma into Phase IIb/III clinical trials and received multiple innovation awards for its trial results.
Company announcements
Everfront Biotech presents updated Cerebraca Wafer results at SNO 2025
The e-poster covers Phase I/IIa trial data for Recurrent Glioblastoma treatment and Phase IIb/III plans. No drug-related adverse effects reported.
Everfront Biotech presents Cerebraca® Wafer trial results at CNS meeting
Phase I/IIa trial shows 15.7 months median survival, no serious adverse events. Plans global Phase IIb trial launch late 2025.
Everfront Biotech unveils Cerebraca® Wafer trial results
Dr. Jen-Wei Liu presents Phase I/IIa outcomes at 2024 Taiwan Healthcare+ Expo, showing 26.2 months median survival and no direct side effects.
Media coverage
Everfront Biotech Files for Proposed IPO
Everfront Biotech (EFB) has filed for a proposed IPO. The company describes itself as: "We are a clinical stage biopharmaceutical company dedicated to the discovery...
Never miss news about EFB
Track EFB and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Trending companies
Discover what's making headlines across other trending companies.
Domyn
Mitsubishi Chemical Group
Teijin
Definium Therapeutics
SUNation
WIN Waste
Avient
Huntsman
Hexcel
Toray
Gurit
SGL Carbon
Ahlstrom
Park.Aero
Pantalones
Sakana AI
PartRunner
Power Integrations
Kroma
SocialLadder
CAMP
Wave
CardMedic
Bevz
InnerPlant
AgVend
Futuremood
Melboss
Geo-Solutions
United Road
Packed Party
Purpose Legal
Allegrow
Sarah Flint
MycRX